Noiiglutide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Noiiglutide is a Chinese long-acting GLP-1 drug. It has published results from a small repeat-dose study in obesity, and a finished final-stage study in type 2 diabetes. It is part of a stream of drug research Western coverage mostly ignores.
Evidence grade for Noiiglutide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Noiiglutide is a long-acting GLP-1 shot from China, the same drug type as Ozempic. It has studies in people with obesity and with type 2 diabetes. It is not approved in the US, the UK, Australia or Canada.
What people take it for
- Weight loss.
- Lower blood sugar in type 2 diabetes.
What studies in people showed
A final-stage study in type 2 diabetes has been finished. In a small study, 40 Chinese adults with obesity took it or a dummy shot. Weight fell 3.3 to 7.5 kg on the drug, against 1.9 kg on the dummy shot. Side effects were mild or moderate, and nobody quit. Ten people per dose is a first look, not an answer. Nobody has tested it head-to-head against Ozempic or Mounjaro.
What people report
Reports, not study results
The good
- In the small study, people lost weight and nobody quit.
The bad
- Side effects in the small study were mild or moderate.
Where these come from: The results and side effects are from the study on this page. We have no forum reports for this one.
My bottom line
This is another GLP-1 that works, and nothing shows it beats the approved ones. If you want this drug type, use an approved one with a doctor watching your blood work.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Noiiglutide?
Noiiglutide is a Chinese long-acting GLP-1 drug. It has published results from a small repeat-dose study in obesity, and a finished final-stage study in type 2 diabetes. It is part of a stream of drug research Western coverage mostly ignores.
A lot of GLP-1 research happens in China. It is published in the same journals as everything else. Yet Western coverage of this field mostly acts as if it does not exist. Noiiglutide is one of several such drugs this site now covers.
It is a long-acting GLP-1 drug from the Chinese company Jiangsu Hengrui. In a small study, 40 Chinese adults with obesity took it or a dummy shot. Weight fell by 3.3 to 7.5 kg on the drug, against 1.9 kg on the dummy shot. Side effects were mild or moderate. A final-stage study in type 2 diabetes has also been finished.
It is not here because it beats approved drugs. Nobody has shown that. It is here because a reader should know the list of drugs in the works is longer than the two or three famous names. A drug being unfamiliar is not the same as it being untested.
How does Noiiglutide work?
Noiiglutide switches on the GLP-1 receptor, the same target as Ozempic. It is built to last a long time in the body, so it does not need frequent shots. It works like the rest of this drug type. It helps the body release insulin when blood sugar is high, lowers a hormone that raises blood sugar, slows the stomach and cuts appetite through the brain.
What have studies in people found about Noiiglutide?
Published results from a small repeat-dose study in obesity, and a finished final-stage study in type 2 diabetes. Early to middle stage proof, with no head-to-head test against an approved drug.
- A final-stage study in type 2 diabetes has been finished.
- 40 Chinese adults with obesity took repeat doses or a dummy shot. Weight fell 3.3 to 7.5 kg on the drug, against 1.9 kg on the dummy shot. Side effects were mild or moderate.
- No head-to-head study against semaglutide, tirzepatide or any approved drug was found.
- The research is based in China, which is where this drug's approval future mostly lies.
What this does not tell you: Safety and blood level results tell you a drug behaves as designed. They do not show it is as good as, or better than, what already exists. Without a head-to-head test, the only honest statement is that this is another GLP-1 drug that works. Studies done in one group of people also leave open how well results carry over to others. That is just as true of Western studies done only in Western people, but people point it out far less often in that direction.
The state of the research
This page exists mostly to fix a blind spot in how the field is covered, not to push a drug.
Read most English writing about GLP-1 drugs and you would think there are about four of them. In fact there is a large second stream of research, much of it in China, publishing careful studies in the same journals as everyone else. This site now covers several of those drugs.
None of them has been tested head-to-head against an approved drug. So nothing here suggests any of them is better. The point is narrower, and worth making. A drug being unfamiliar to a Western reader is not the same as it being untested. A site that claims to show what has been measured should show what has actually been measured, not just what has been marketed loudly.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- A long-acting peptide analogue. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Long-acting, engineered for infrequent subcutaneous dosing. No specific figure was resolved in the sources loaded.
No amino acid sequence is on file for Noiiglutide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects
People lost weight on noiiglutide in an early Chinese study, and the study was tiny. 40 Chinese adults with obesity and no diabetes took a daily shot, built up to one of four target doses over three to six weeks. In each dose group, eight got the drug and two a dummy shot. Weight fell 3.3 to 7.5 kg on the drug, against 1.9 kg on the dummy shot. Side effects were mild or moderate, and nobody quit. Ten people per dose is a first look, not an answer.
A randomised controlled multiple-dose study in Chinese participants with obesity, reporting safety, pharmacokinetics and pharmacodynamics. Peer-reviewed in a mainstream journal, which is worth noting given how often non-Western development is treated as though it were unpublished.
- Study in people2026Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: a randomized, double-blind, phase 1b/2a study
A rival Chinese long-acting GLP-1 drug lowered blood sugar in its own study. 72 adults in China with type 2 diabetes took weekly bofanglutide or a dummy shot, and 62 finished. Average blood sugar fell by 1.32 and 1.81 points on two dose plans, while it rose slightly on the dummy shot. Weight also improved. Side effects were mostly mild stomach upset. This shows how crowded the field is. It is not proof about noiiglutide. Gan and Lee paid for it.
A parallel Chinese long-acting GLP-1 programme, bofanglutide, published in a high-profile journal. Included as context for the breadth of this development stream rather than as evidence about noiiglutide itself.
Where to buy Noiiglutide
No seller we track lists Noiiglutide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Noiiglutide been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Noiiglutide is a Chinese long-acting GLP-1 drug. It has published results from a small repeat-dose study in obesity, and a finished final-stage study in type 2 diabetes. It is part of a stream of drug research Western coverage mostly ignores.
What is the Noiiglutide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Noiiglutide FDA-approved?
Not approved in the United States. Developed in China, where its status with regulators is different.
Is noiiglutide better than semaglutide?
Nobody has compared them, so there is no basis for saying so. What exists is a small repeat-dose study in obesity and a finished final-stage study in type 2 diabetes. That shows it works as a GLP-1 drug. It does not show it works better than one already approved.
Why is a Chinese drug on this site?
Because its studies are published in the same journals as everything else here. A site that claims to show what has been measured should not filter by where the measuring happened. There is a large second stream of research on this drug type that most English coverage leaves out.
Can I get it?
Not legally outside the markets where it is being developed. It is not approved in the United States, the United Kingdom, Australia or Canada.